Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow

Pediatric Blood and Cancer

Volumn 45, Issue 6, 2005, Pages 787-795

  Okcu, Mehmet Fatih ^a,b,f   Wang, Rui Yu ^a   Bueso Ramos, Carlos ^a   Schober, Wendy ^a   Weidner, Douglas ^a,c   Andrassy, Richard ^a   Blakely, Martin ^a   Russell, Heidi ^b   Ozkan, Alp ^a,d   Kuttesch, John ^a,e   Andreeff, Michael ^a   Chan, Ka Wah ^a   Ater, Joann ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS CHILDREN S CANCER CENTER   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d ISTANBUL UNIVERSITY   (Turkey)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Flow cytometry; Neuroblastoma; Residual disease

Indexed keywords

CD45 ANTIGEN; CD56 ANTIGEN; CD9 ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; ANALYTIC METHOD; ARTICLE; BONE MARROW; CHILD; CHROMOSOME 17Q; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MINIMAL RESIDUAL DISEASE; MORPHOLOGY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; ANTIGENS, CD; BONE MARROW; BONE MARROW EXAMINATION; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; NEOPLASM, RESIDUAL; NEUROBLASTOMA; SENSITIVITY AND SPECIFICITY;

EID: 26244436647     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20428     Document Type: Article

References (48)

1. Ries LAG, SMith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program. 1999.
2. Cotterill SJ, Pearson AD, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 2000;36:901-908.
3. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma [see comments]. N Engl J Med 1999;340:1954-1961.
4. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome Ip as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-230.
5. Haase GM, Perez C, Atkinson JB. Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol 1999;16:91-104.
6. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
7. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87:1470-1476.
8. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 2001;92:2451-2461.
9. Castel V, Garcia-Miguel P, Canete A, et al. Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. Eur J Cancer 1999;35:606-611.
10. Matthay KK. Neuroblastoma: Biology and therapy. Oncology 1997;11:1857-1866.
11. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over I year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999;23:789-795.
12. Matthay KK, O'Leary MC, Ramsay NK, et al. Role of myelo-ablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 1995;31A:572-575.
13. Cohn SL, Moss TJ, Hoover M, et al. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transpl 1997;20: 543-551.
14. Ladenstein R, Lasset C, Hartmann O, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: Report from the European Group for Bone Marrow Transplantation. Bone Marrow Transpl 1994;14:37-46.
15. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group. J Clin Oncol 1994;12:2382-2389.
16. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
17. Seeger RC, Villablanca JG, Matthay KK, et al. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 1991;366:527-533.
18. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997;33:2130-2135.
19. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996;14:2417-2426.
20. Brenner MK, Rill DR, Moen RC, et al. Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci 1994;716: 204-214.
21. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-383.
22. Cheung NK, Heller G, Kushner BH, et al. Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive? J Clin Oncol 1997;15:2807-2817.
23. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001;19:1795-1801.
24. Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998;4:2801-2805.
25. Cheung IY, Cheung NK. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 1997;3:821-826.
26. Cheung NK, Von Hoff DD, Strandjord SE, et al. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986;4:363-369.
27. Favrot MC, Frappaz D, Maritaz O, et al. Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow. Br J Cancer 1986;54:637-641.
28. Lode HN, Handgretinger R, Schuermann U, et al. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer 1997;33:2024-2030.
29. Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol 1990;8:736-740.
30. Moss TJ, Reynolds CP, Sather HN, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-226.
31. Tchirkov A, Kanold J, Giollant M, et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 1998;30:228-232.
32. Wang Y, Einhorn P, Triche TJ, et al. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors. Clin Cancer Res 2000;6:551-558.
33. Komada Y, Zhang XL, Zhou YW, et al. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer 1998;82:591-599.
34. Ebener U, Wehner S, Cinatl J, et al. Expression of markers shared between human haematopoietic cells and neuroblastoma cells. Anticancer Res 1990;10:887-890.
35. Mechtersheimer G, Barth T, Ludwig R, et al. Differential expression of leukocyte differentiation antigens in small round blue cell sarcomas. Cancer 1993;71:237-248.
36. Nagai J, Ishida Y, Koga N, et al. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol 2000;22:20-26.
37. Plantaz D, Mohapatra G, Matthay KK, et al. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 1997;150:81-89.
38. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
39. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-1881.
40. Cheung NK, Morris MD. Detection of microscopic residual tumors in bone marrow. In: Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Neuroblastoma 1st edn. Amsterdam: Elsevier Science B. V. 2000. pp 333-340.
41. Moss TJ. Sensitive detection of metastatic tumor cells in bone marrow. Prog Clin Biol Res 1994;389:567-577.
42. Cheung IY, Lo Piccolo MS, Kushner BH, et al. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 2003;21:3853-3858.
43. Cheung IY, Lo Piccolo MS, Kushner BH, et al. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: Clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003;21:1087-1093.
44. Lambooy LH, Gidding CE, van den Heuvel LP, et al. Real-time analysis of tyrosine hydroxylase gene expression: A sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Clin Cancer Res 2003;9:812-819.
45. Tchirkov A, Paillard C, Halle P, et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res 2003;12:435-442.
46. Cheung IY, Cheung NK. Detection of microscopic disease: Comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol 2001;36: 210-212.
47. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 2000;18:4067-4076.
48. Tsang KS, Li CK, Tsoi WC, et al. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction. Cancer 2003;97:2887-2897.